Clinical Trial

A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will enroll adults with confirmed metastatic pancreatic ductal adenocarcinoma (PDAC, systemic PDAC treatment naïve), Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, and adequate organ function. Participants will receive pumitamig (also known as BNT327, BMS-986545, or PM8002) in combination with chemotherapy.
Protocol Amendment History 2 changes
notable Trial sites expanded: 10 -> 24 locations 2026-07-29
notable Trial sites expanded: 1 -> 10 locations 2026-04-30
Trial Details
NCT Number NCT07255404
Lead Sponsor BioNTech SE
Collaborators: Bristol-Myers Squibb, BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
Conditions Pancreatic Ductal Adenocarcinoma (PDAC)
Enrollment 105 participants
Start Date 2025-12-04
Primary Completion 2027-12 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-28